![]() ![]() One particularly well-characterized circuit regulating innate immunity, the inflammatory reflex, is dependent upon action potentials transmitted to the reticuloendothelial system via the vagus and splenic nerves. The discovery is that neuronal circuits operating reflexively regulate innate and adaptive immunity. That cornerstone of attention has been expanded by recent discoveries that neuronal signals occupy a critical regulatory niche in immunity. However, this antibody is not intended to replace COVID-19 vaccines, which remain the most effective way to prevent infection.The field of immunology is principally focused on the molecular mechanisms by which hematopoietic cells initiate and maintain innate and adaptive immunity. It opens the door to improved treatments for severe forms of the disease and to enhanced prophylactic measures, especially for patients with weakened immune systems. The discovery of this new antibody marks a major step forward in the fight against COVID-19. Pantaleo's department at CHUV also received support from the Corona Accelerated R&D in Europe (CARE) program, which is part of the Innovative Medicine Initiative (IMI)-a public-private partnership that seeks to address bottlenecks in the drug discovery and development process in Europe. The research team was able to respond to the pandemic and discover this neutralizing antibody so quickly thanks to the multi-year support of the Swiss Vaccine Research Institute. Craig Fenwick, and by EPFL's Laboratory of Virology and Genetics, headed by Prof. This research was conducted jointly by CHUV's Service of Immunology and Allergy, headed by Prof. Clinical trials of the drug should begin in late 2022. Immunocompromised patients, organ transplant recipients and those suffering from certain kinds of cancer could be protected against SARS-CoV-2 by receiving antibody injections two or three times a year.ĬHUV and EPFL now plan to build on these promising results in association with a start-up company which will perform clinical development and production of the antibody-containing drug, through cooperation and intellectual property agreements. That makes it an interesting preventive-treatment option for unvaccinated at-risk individuals or for vaccinated individuals who are unable to produce an immune response. But this new one can protect patients for 4-6 months. A typical unaltered antibody provides protection for up to 3-4 weeks. In addition to its antiviral properties, the new antibody is designed to have a lasting effect in humans. This protective mechanism was proven through in vivo tests on hamsters specimens that were administered the antibody were protected against infection even after receiving a highly infectious dose. That means the antibody halts the viral replication process, enabling a patient's immune system to eliminate SARS-CoV-2 from the body. Through this tight interaction, the antibody blocks the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor the virus uses to enter and infect lung cells. Structural characterization of the antibody indicates that it binds to an area that is not subjected to mutations of the spike protein. ![]() This antibody is one of the most powerful identified so far against SARS-CoV-2. The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV study being carried out by CHUV's Service of Immunology and Allergy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |